Last reviewed · How we verify

rSIFN-co Nasal Spray

Sichuan Huiyang Life Science and Technology Corporation · Phase 2 active Small molecule

rSIFN-co Nasal Spray is a Small molecule drug developed by Sichuan Huiyang Life Science and Technology Corporation. It is currently in Phase 2 development. Also known as: rSIFN-co.

At a glance

Generic namerSIFN-co Nasal Spray
Also known asrSIFN-co
SponsorSichuan Huiyang Life Science and Technology Corporation
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about rSIFN-co Nasal Spray

What is rSIFN-co Nasal Spray?

rSIFN-co Nasal Spray is a Small molecule drug developed by Sichuan Huiyang Life Science and Technology Corporation.

Who makes rSIFN-co Nasal Spray?

rSIFN-co Nasal Spray is developed by Sichuan Huiyang Life Science and Technology Corporation (see full Sichuan Huiyang Life Science and Technology Corporation pipeline at /company/sichuan-huiyang-life-science-and-technology-corporation).

Is rSIFN-co Nasal Spray also known as anything else?

rSIFN-co Nasal Spray is also known as rSIFN-co.

What development phase is rSIFN-co Nasal Spray in?

rSIFN-co Nasal Spray is in Phase 2.

Related